China Dasatinib Market Survey Report 2016-2020 & 2021-2025: An Anti-tumor Drug Developed by Bristol-Myers Squibb – | Nation/World



the “China Dasatinib Market Investigation Report 2021-2025” report has been added to ResearchAndMarkets.comoffer.

Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic and accelerated phases who are resistant or intolerant to prior therapy with imatinib. In 2011, Dasatinib was approved in China. By 2020, the two manufacturers in China’s dasatinib market are Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Bristol-Myers Squibb Pharma EEIG.

According to market research, sales of Dasatinib increased year-on-year from 2016 to 2020, with the highest growth in 2018. The annual growth rate is 48.72%, from CNY 51 million in 2017 to CNY 75 million in 2018. The main reason for the increase is that China has embarked on an effort to reduce healthcare costs, requiring insurance to cover 70% of costs since national drug price negotiations in 2017. Dasatinib sales CAGR in 2016-2020 is 28.55%.

The analyst analyzes that its sales will have an upward trend from 2021 to 2025 as the Chinese Dasatinib market develops. At present, 3 companies in China are in the approval phase of Dasatinib generic drugs. After the success of the approvals, the competition in the Chinese Dasatinib market will become more intense and the price will be lower than before.

Therefore, the sales volume will increase accordingly. Additionally, Dasatinib has been approved for 4 indications internationally, and only 2 indications have been approved in China. The number of indications approved in China is likely to increase, so sales still have the potential to increase.

Topics Covered:

  • The impact of COVID-19 on the Chinese Dasatinib market
  • Dasatinib sales value in China 2016-2020
  • Competitive Landscape of China Dasatinib Market
  • Dasatinib price in China
  • Dasatinib Price in China by Regions and Manufacturers
  • Analysis of factors affecting the development of China Dasatinib market
  • China Dasatinib Market Outlook 2021 to 2025

Main topics covered:

1 Relevant concepts of dasatinib

1.1 Indications for dasatinib

1.2 Development of Dasatinib in China

1.3 Government approval of dasatinib in China

1.4 The impact of COVID-19 on Dasatinib sales in China

2 China Dasatinib Sales, 2016-2020

2.1 Dasatinib Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Regions

2.2 Dasatinib Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 China Dasatinib Sales by Dosage Form, 2016-2020

2.3.1 Tablet

2.3.2 Analysis of other dosage forms

3 Analysis of Dasatinib Key Manufacturers in China, 2016-2020

3.1 Dasatinib Major Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.2.1 Company profile

3.2.2 China Yinishu (Dasatinib by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) Sales

3.3 Bristol-Myers Squibb Pharma EEIG

3.3.1 Company Profile

3.3.2 SPRYCEL (Bristol-Myers Squibb Pharma EEIG Dasatinib) Sales in China

4 Dasatinib Price for Different Manufacturers in China, 2020-2021

4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Yinish)

4.2 Bristol-Myers Squibb Pharma EEIG (SPRYCEL)

5 China Dasatinib Market Outlook, 2021-2025

5.1 Influencing Factors of China Dasatinib Market Development

5.1.1 The impact of COVID-19 on the Chinese Dasatinib market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit

Show source version on


Laura Wood, Senior Press Officer

[email protected] EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900



SOURCE: Research and Markets

Copyright BusinessWire 2022.

PUBLISHED: 03/07/2022 12:18 PM / DISK: 03/07/2022 12:18 PM


Comments are closed.